Marizyme, Inc. Receives FDA Feedback on Development Plan for Krillase(TM) in Pediatric Stroke

Author's Avatar
Apr 12, 2019
Article's Main Image

FORT COLLINS, CO / ACCESSWIRE / March 15, 2019 / Marizyme, Inc. ("Marizyme" or the "Company"), a publicly traded (OTC PINK: MRZM) company focusing on acquiring late-stage drug assets for use in the acute care space for development and commercialization, announced today that they have received FDA feedback regarding their development plan for Krillaseâ„¢ (MB102) in pediatric stroke. In preparation for initiating development activities for MB102, Marizyme requested feedback from the FDA using a Pre-IND application for a Type B meeting request.